Seeing Is Believing

Currently out of the existing stock ratings of Justin Zelin, 126 are a BUY (96.92%), 4 are a HOLD (3.08%).
Analyst Justin Zelin, currently employed at BTIG, carries an average stock price target met ratio of 20.97% that have a potential upside of 37.78% achieved within 81 days.
Justin Zelin’s has documented 244 price targets and ratings displayed on 33 stocks. The coverage is on Healthcare, Industrials, Energy, Technology sectors.
Most recent stock forecast was given on IBRX, Immunitybio at 23-Jan-2026.
Analyst best performing recommendations are on MRSN (MERSANA THERAPEUTICS).
The best stock recommendation documented was for VKTX (VIKING THERAPEUTICS) at 2/8/2024. The price target of $36 was fulfilled within 8 days with a profit of $7.11 (24.61%) receiving and performance score of 30.76.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy Since 15-Oct-2017
$18
$15.7 (682.61%)
$20
Buy Since 07-Nov-2022
$30
$27.7 (1204.35%)
$28
1 months 27 days ago
(17-Sep-2026)
1/6 (16.67%)
$24.43 (438.60%)
1
Buy Since 16-Mar-2026
$21
$18.7 (813.04%)
$22
3 months ago
(13-Aug-2026)
0/2 (0%)
$15.01 (250.58%)
Buy Since 28-Apr-2025
$17
$14.7 (639.13%)
$19
7 months 28 days ago
(16-Mar-2026)
0/4 (0%)
$12.24 (257.14%)
Buy Since 01-Jun-2025
$22
$19.7 (856.52%)
$20
8 months 5 days ago
(08-Mar-2026)
0/3 (0%)
$16.84 (326.36%)
What Year was the first public recommendation made by Justin Zelin?